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Hematologic myeloid neoplasms represent a heterogeneous group of disorders with defined
clinical and pathologic characteristics. However, intensive investigation into the genetic abnor-
malities of these diseases has not only significantly advanced our understanding, but also rev-
olutionized our diagnostic and prognostic capabilities. Moreover, more recent discovery on the
impact of clonal burden has highlighted the critical and dynamic role of clonal evolution over
time, which is integrally linked to a patient’s clinical trajectory. This review will highlight the
evidence supporting the incorporation of allelic burden of somatic mutations into clinical prac-
tice for the diagnosis and prognosis of myeloid neoplasms.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Next-generation sequencing (NGS) has brought forth a para-
digm shift in the diagnosis, prognosis, and therapeutic man-
agement of patients with myeloid neoplasms [1]. Whole-
genome and exome sequencing in myeloid neoplasms have
led to the near-complete annotation of recurrent mutationsin acute myeloid leukemia (AML), myelodysplastic syn-
dromes (MDSs), and many myeloproliferative neoplasms
(MPNs), identifying mutations in the vast majority of cases
[2–7]. Although current commercial NGS technologies typi-
cally report pathogenic mutations that are present at a
mutational burden of at least 5%, sufficient sequencing
depth allows for mutation detection at frequencies that
approach 1% and novel technologies are in development
for the identification of variants with much lower variant
allele frequency (VAF) thresholds. These technological
advances in NGS have led to the identification of rare
variants that may be prognostically important and reveal
90 D.A. Sallman, E. Padronpreviously unidentified intratumoral genetic complexity.
Collectively, this has led to several studies that have lever-
aged genomic data to classify diagnostically relevant sub-
sets of AML, MDS, and MPNs that, in many cases, are both
prognostic and predictive of clinically relevant
therapeutics.
NGS can quantitate the proportion of variant reads for a
given mutation, also known as the VAF, which represents
the percentage of tumor cells that harbor a specific muta-
tion assuming a relatively pure leukemic sample. This allows
for the digital quantitation of mutational burden; however,
to date, the clinical implementation of mutational analysis
has largely been of a binary nature with pathogenic muta-
tions being reported only as either positive or negative.
Recent studies on myeloid neoplasms have elucidated a
novel clinical role of clonal burden/VAF in all facets of
the clinical management of these patients. In this review,
we will summarize the data that evaluate the clinical utility
and implementation of mutational burden in myeloid
malignancies.
Next-generation sequencing: the basics
Unlike conventional Sanger sequencing that resolves the
sequence of a small genomic region, NGS is a digital tech-
nology that sequences large portions of segmented genomic
regions in parallel and has been previously reviewed [1,8].
In NGS, by using chip-based approaches, the individual
sequence of each genomic region is resolved (or read) and
computationally aligned against a reference genome [8].
Mutations or variants are then defined as differences
between the reference genome and the aligned reads.
Direct comparisons of these variants between a leukemic
sample and a germ-line control, or in silico approaches,
allow for the identification of true somatic mutations.
For clinical NGS, small regions of the genome are interro-
gated allowing for hundreds, if not thousands, of reads to be
mapped to similar regions that allow for the sequential anal-
ysis of the same genomic coordinate. Quantification of
these variants detected can be simply calculated by dividing
the number of reads with the variant against the total num-
ber of reads at the genomic position in question. Care
should be taken to recognize areas of the genome that are
difficult to align or with somatic insertions and deletions
as these may be difficult to quantitate.
Allele burden on phenotype and outcomes in
MPN
A point mutation in Exon 14 of the Janus kinase 2 gene (JAK2
V617F) has been identified in the Philadelphia chromosome-
negative MPNs, which include polycythemia vera (PV),
essential thrombocythemia (ET), and primary myelofibrosis
(PMF). The mutation (JAK2 V617F) occurs in approximately
95% of PV patients and 50–60% of ET/PMF patients, as con-
firmed in multiple studies [9,10]. Importantly, JAK2 V617F
VAF has been found to be tightly coupled to clinical pheno-
type in MPNs (Table 1) [11]. Specifically, homozygous muta-
tions of JAK2 V617F, which have VAF > 50%, are significantly
more common in PV than in ET (25–30% vs. 2–4%) and asso-ciated with higher white blood cell counts, hematocrit, and
splenomegaly [12]. In addition, JAK2 V617F VAF can help
differentiate prefibrotic PMF from ET, as a VAF > 50%
strongly favors PMF [13].
VAF has also been associated with clinical course in
MPNs. In PV and ET, the JAK2 V617F allele burden identifies
a subgroup of patients with a more aggressive phenotype.
Specifically, ET patients who are homozygous for JAK2 have
an increased rate of thrombotic events [12]. In both PV and
ET, JAK2 VAF has been associated with a higher rate of
fibrotic transformation [12,14,15]. In contrast to ET, the
association of JAK2 allele burden with thrombosis in PV
has been controversial. However, one large prospective
study reported that patients with a VAF > 75% had the high-
est risk of thrombosis (approximately 3.5-fold) and were
associated with elevated white blood cell counts [16]. Fur-
ther, a more recent study showed that over time (>5 years
after diagnosis), increasing JAK2 VAF was shown to be the
strongest predictor of recurrent thrombosis irrespective of
specific MPN diagnosis [17]. In PMF, patients with a JAK2
allele burden in the lowest quartile had shorted leukemia-
free survival (LFS) and overall survival (OS) [18]. The corre-
lation of a low JAK2 allele burden with inferior outcomes in
PMF has been validated in a follow-up study and is indepen-
dently prognostic in multivariable analysis [19].
Because both studies clinically identified patients with
low JAK2 VAF in a myelodepletive rather than a myeloprolif-
erative state, the negative prognosis of these patients may
be driven by the acquisition of additional driver mutations.
In support of this hypothesis, targeted NGS of 104 genes in
197 MPN patients evaluated clonal evolution with respect
to clinical outcomes and determined these processes to be
integrally related [6]. Acquisition of more than one somatic
mutation predicted for the risk of leukemic transformation
as well as inferior OS and highlighted the deleterious effect
of TP53 clonal expansion. Serial analysis of TP53mutation in
these MPN patients identified that dramatic VAF increases
occur at the time of transformation, thus suggesting that
TP53 VAF may be associated with leukemic transformation
in MPNs. Specifically, four patients had serial samples with
an initial VAF < 10% in all cases, which was stable for years
[6]. Loss of the wild-type (WT) TP53 allele occurred in three
cases followed by rapid clonal expansion (VAF > 50%). Fol-
lowing this clonal expansion, all patients transformed to
AML, except one patient who continued to have subclonal
TP53 mutation and did not transform. Further supporting
the role of TP53 in MPN leukemic transformation, alter-
ations of the p53 pathway (either mutation or amplification
of chromosome 1q) occurred in 45% of post-MPN AML cases
[20]. Amplification of chromosome 1q can inhibit WT p53
expression through overexpression of MDM4, a known
potent suppressor of p53. In the two cases where samples
were available from the chronic MPN stage, both had evi-
dence of the TP53 mutation in a subclone. Given that mul-
tiple studies have shown that the presence of a TP53
subclone is a predictor of eventual leukemic transforma-
tion, this could have important therapeutic ramifications
given the propensity for cytotoxic chemotherapies to lead
to TP53 clonal expansion (Figure 1).
In ET and PMF patients who are negative for JAK2
V617F, point mutations of the thrombopoietin receptor
Table 1 Impact of JAK2 V617F and TP53 VAF on MPN.
Diagnosis Genetic association
PV versus ET Homozygous mutation in PV
ET versus prefibrotic PMF JAK2 VAF > 50% in PMF
Phenotype
Leukocytosis " JAK2 VAF
Higher hematocrit " JAK2 VAF
Splenomegaly " JAK2 VAF
Outcomes
Fibrotic transformation (PV and ET) " JAK2 VAF/homozygous mutation
Thrombosis (ET ± PV) " JAK2 VAF (>75% in PV)
Leukemic transformation ; JAK2 VAF in PMF (lowest quartile); " TP53 VAF
Inferior overall survival ; JAK2 VAF in PMF (lowest quartile); " TP53 VAF
Note: ET = essential thrombocythemia; MPN = myeloproliferative neoplasm; PMF = primary
myelofibrosis; PV = polycythemia vera; VAF = variant allele frequency.
Figure 1 Model for the impact of TP53 variant allele frequency on disease progression in myeloid neoplasms. Although TP53
mutation in chronic myeloproliferative neoplasms (MPNs) is a rare event, subclonal mutations can occur. TP53 clonal expansion
strongly correlates with leukemic transformation in MPN. Acquisition of TP53 mutation is typically a secondary event in
myelodysplastic syndromes (MDSs), although it can be present in the preleukemic state, and is tightly coupled with inferior
outcomes, which are directly correlated with the clonal burden of TP53. Therapy-related MDS and acute myeloid leukemia (AML)
likely develops through the potentiation of very rare subclones present prior to treatment with a prolonged latency period. Note: t-
AML = therapy-related AML; t-MDS = therapy-related MDS.
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[21,22]. Although patients with MPL W515K mutations had
significantly higher VAF than patients with MPL W515L,
there were no phenotypic differences [22]. Using whole-
exome sequencing in JAK2/MPL-negative ET and PMF
patients, recent data have demonstrated that mutations
of the calreticulin gene (CALR) occur in 67–71% and 56–
88% of patients, respectively [23,24]. Mutations of CALR
are indels and occur nearly exclusively in Exon 9, leading
to a mutant protein with a novel C-terminal domain.
Approximately 50% of patients have a Type 1 mutation
(52 base pair deletion) with 30% of patients having a Type
2 mutation (5 base pair insertion). Importantly, CALR-
mutant patients were found to have a more indolent clin-
ical course with a lower thrombosis risk and a longer OS in
comparison with JAK2-mutant patients [23]. Although phe-notypic differences among CALR-mutant patients have not
been described, CALR allele burden, as quantified by a
fragment analysis assay, could prove to be important for
monitoring response in patients treated with interferon
alfa [25,26]. Whereas hydroxyurea had no impact on allele
burden of CALR in ET patients, interferon alfa was able to
induce molecular remissions in 42% (13/31) of patients
[26]. Of interest, the presence of additional mutations
identified by NGS was predictive of clonal remissions, as
patients with isolated CALR mutations had at least partial
molecular remission (VAF reduction > 50%): 13/24 patients
with isolated CALR mutations versus 0/6 patients with an
additional mutation. Whether or not targeting clonal
remissions in CALR-mutant myeloid neoplasms is clinically
important will need to be addressed in prospective clinical
trials.
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hematologic malignancy
It is now recognized that somatic myeloid mutations are
present in individuals without hematologic cytopenias in
approximately 5–10% of patients over the age of 65 years
and at VAF thresholds that can be identified by commer-
cially available NGS technologies [27–29]. These individuals
were characterized by the acquisition of one mutation, on
average, which occurred at a relatively low VAF. Although
the development of a hematologic malignancy was uncom-
mon (1%/year) in the entire mutant cohort, the risk was
50-fold higher in individuals with a higher clonal burden
(VAF > 10%). Overall, these data implicate a direct correla-
tion with clinical trajectories and mutational allelic burden
in myeloid neoplasms [28]. Indeed, VAF assessment will
likely allow for improved prediction of patients who will
ultimately progress to overt hematologic malignancy. To
this end, a recent study performed NGS at the time of a non-
diagnostic bone marrow biopsy and at definitive progression
to MDS and/or AML [30]. The VAF of patients who ultimately
developed MDS/AML was significantly increased with a med-
ian VAF of 40% versus 9–10% reported in the aforemen-
tioned studies with age-related clonal hematopoiesis
[27,28]. In addition, patients who developed disease fre-
quently had additional mutations, thus highlighting that
the overall mutational burden is a strong predictor for the
clinical significance of somatic mutations and may assist in
the differentiation of what has recently been termed as clo-
nal hematopoiesis of indeterminate potential from bona
fide MDS [31]. As proof of principle, a recent report pre-
sented a case of a patient who received an allogeneic bone
marrow transplantation (BMT) for relapsed lymphoma where
both the donor and the recipient developed AML within
4 months [32]. It was subsequently determined that the
donor had a preleukemic DNMT3A clone with a high allele
burden (46%) that ultimately led to the development of
two genetically distinct leukemic clones through the acqui-
sition of additional mutations.
Therapy-related MDS (t-MDS) and therapy-related AML (t-
AML) have been classically associated with alkylating agents
and other cytotoxic therapies and are enriched for aberra-
tions of chromosome 5/7, complex cytogenetics, as well
as TP53 mutations [33–35]. More importantly, we and
others have shown that TP53 mutation is the critical nega-
tive prognostic factor as TP53 mutation patients have infe-
rior outcomes in comparison with even historically poor-risk
patients with complex cytogenetics and/or monosomal
karyotype [36–38]. The question of the causal relationship
between cytotoxic therapy and TP53 mutation has been
advanced. Specifically, Wong and colleagues [39] have
recently shown that TP53 clones (at a very low VAF of
0.003–0.07%) were identified in the peripheral blood or
bone marrow in four of seven patients some years prior to
the diagnosis of t-AML/t-MDS. Importantly, these rare
TP53 clones were detected in two patients prior to receiving
any cytotoxic therapy. These data were further recapitu-
lated in an in vivo model, suggesting that patients can be
predisposed to therapy-related hematologic neoplasms sec-
ondary to hematopoietic stem/progenitor cells harboring
age-related TP53 somatic mutations (Figure 1). Using thisnovel adaptor sequencing assay with confirmation by dro-
plet digital polymerase chain reaction, the authors were
able to show that these very rare variants are found com-
monly (approximately 50%) in healthy elderly patients.
Given the current dismal prognosis of TP53-mutant patients,
avoiding cytotoxic chemotherapies that could potentiate
TP53 clonal expansion may not only be an important aspect
in the treatment of patients with hematologic malignancy,
but also in solid malignancy when there are equivalent
chemotherapeutic options that do not have this risk. In
addition, the presence of rare clones has been found to be
prognostically relevant in low-risk MDS patients [40]. Using
highly sensitive polymerase chain reaction technology for
NRAS mutations (variant detection threshold of 0.02–
0.1%), the investigators were able to demonstrate in a mul-
tivariable analysis that a VAF threshold of 0.5% predicted for
inferior outcomes. As technological advances increasingly
improve the sensitivity for detecting rare variants, it will
be important to redefine their relative impact on the clini-
cal care of patients with myeloid malignancies.VAF further refines prognostication in AML
Fms-related tyrosine kinase 3-internal tandem duplications
(FLT3-ITDs) represent the most common mutation in AML
(approximately 30%) and are associated with inferior sur-
vival in multiple studies [5,41]. The clonal burden of FLT3-
ITD has been reported to further improve prognostication.
Indeed, loss of the WT allele was shown to predict for infe-
rior survival in comparison with FLT3-ITD in the heterozy-
gous state [42]. In addition, in the evaluation of
prospective clinical trials within the German–Austrian AML
Study Group, Schlenk and colleagues [43] identified that a
high allelic ratio (ARP 0.51) of FLT3-ITD resulted in inferior
complete response rates as well as inferior OS and
progression-free survival. More importantly, only the poor-
risk high AR subgroup benefited from allogenic BMT, which
was confirmed in a multivariable analysis. As the clonal
architecture of AML has been increasingly defined, combina-
tions of gene mutations have led to contrasting data on their
relative prognostic impact, as has occurred in patients with
comutated FLT3-ITD and nucleophosmin (NPM1) [44]. The
mutation load of FLT3-ITD is able to elucidate the group
of patients who truly have an inferior survival in the context
of comutation with NPM1. Specifically, only patients with an
FLT3-ITD of 0.5 or more had inferior event-free survival
(EFS) and OS [45]. Furthermore, FLT3-ITD as a continuous
variable predicted inferior EFS. As an example, patients
with an FLT3-ITD of 1 had inferior outcomes compared with
patients with an FLT3-ITD of 0.5–1. In addition, patients
with an FLT3-ITD < 0.5 did not have inferior outcomes in
comparison with FLT3 WT patients. These data provide evi-
dence that NPM1-mutant patients who have FLT3-ITD with a
ratio < 0.5 also have favorable outcomes and may not bene-
fit from early allogeneic BMT. The aforementioned study
confirmed results from the Medical Research Counsel
cohort, which also demonstrated that an FLT3-ITD threshold
of 0.5 was an independent prognostic factor for EFS and OS
[46]. However, the exact threshold remains controversial as
a previous study identified a threshold of 0.78 to be predic-
tive for LFS and OS [47]. Therefore, future multicenter
Table 2 Impact of clonal burden on phenotype and
outcomes in myelodysplastic syndromes.
Phenotype Genetic association
% of BM ringed sideroblasts " SF3B1 VAF
Monocytosis " SRSF2 VAF
(SRSF2/TET2 comutant)
Thrombocytopenia " RUNX1 VAF
Complex cytogenetics " TP53 VAF
Outcomes
LFS/OS with HMA ?
LFS/OS with allogeneic BMT ?
Disease progressiona " TP53 VAF
OS " TP53 VAF (>20–40%)
Note: BM = bone marrow; BMT = bone marrow transplantation;
HMA = hypomethylating agent therapy; LFS = leukemia-free sur-
vival; OS = overall survival; VAF = variant allele frequency.
a Progression to higher risk myelodysplastic syndrome or acute
myeloid leukemia.
Variant allele frequency in myeloid malignancies 93investigation will be required to define the optimal cutoff of
FLT3-ITD, given the important therapeutic ramifications,
particularly its indication for allogeneic BMT in CR1.
The FLT3-ITD AR can also be used to predict sensitivity to
FLT3 inhibition, which has been a major focus in recent
years to improve the outcomes of this high-risk subgroup.
Of interest, primary AML samples with a high AR were signif-
icantly more sensitive to FLT3 inhibition than their low AR
counterparts [48]. This has important clinical implications
in that FLT3-ITD AR is often increased at relapse compared
with FLT3-ITD AR at diagnosis where FLT3-ITD is commonly
in a heterozygous/subclonal state [49,50]. Indeed, all
relapsed samples or de novo samples with high FLT3-ITD
AR (>50%) were selectively sensitive to FLT3 inhibitors.
These data highlight the concept of oncogene addiction,
suggesting that clonal burden can be used as a surrogate
for the degree of addiction and potentially used for thera-
peutic personalization. Whether FLT3-ITD AR will be an
important biomarker to stratify the beneficial effect of
FLT3 inhibition needs to be investigated in future prospec-
tive clinical studies.
VAF predicts phenotype in MDS
Recently, highly specific genotype–phenotype associations
have been elucidated including SF3B1 mutation with refrac-
tory anemia with ringed sideroblasts and comutations of
SRSF2/TET2 with chronic myelomonocytic leukemia (CMML)
[2,51–53]. In addition, SF3B1 VAF strongly predicted for the
percentage of ringed sideroblasts, which has been recently
confirmed [38,54]. Given the comutation of SRSF2 or ZRSR2
with TET2, which has a specificity as high as 98.4% for CMML
[53], a previous study investigated whether VAF correlated
with the degree of monocytosis. Indeed, SRSF2 VAF directly
correlated with both the presence and degree of monocyto-
sis. Although the authors did not find an association with
ZRSR2 VAF, future study is needed as this mutation was only
present in a small subset of patients [38].
As multiple studies have associated TP53 mutation with
complex cytogenetics, the possible association betweenTP53 VAF and the presence of complex cytogenetics was
investigated [38]. Not only did the vast majority of patients
with a dominant TP53 clone have complex cytogenetics
(80–100% vs. 40–50% in subclonal TP53 mutation), TP53
VAF directly correlated with the number of cytogenetic
abnormalities, suggesting that TP53 clonal expansion is inte-
grally related to genome instability. Finally, we also found
an association with the presence and severity of thrombocy-
topenia with RUNX1 VAF. As recent studies have identified
molecular predictors of response to hypomethylating agent
therapy (i.e., ASXL1 WT/TET2 mutant) as well as inferior
survival with allogeneic BMT [37,55], future investigation
is required to determine the impact of VAF on response
and outcomes to treatment. Ideally, enhanced understand-
ing of the driver mutations in MDS will ultimately lead to
novel targeted therapies. Table 2 presents the molecular
abnormalities in MDS that define clinical phenotype and
outcomes.TP53 VAF improves prognostication over
binary mutation analysis alone in MDS
In a landmark paper, Bejar and colleagues [7] investigated
the prognostic significance of somatic mutations in MDS
and discovered that mutations in one of the five genes
(ASXL1, EZH2, ETV6, RUNX1, and TP53) were independently
predictive of inferior OS in both univariable and multivari-
able analyses [7]. More importantly, the presence of any
one of these mutations translated into a prognosis similar
to the next highest risk International Prognostic Scoring Sys-
tem (IPSS) category, effectively upstaging the prognostic
category. In addition, TP53-mutant patients had inferior
OS to hypomethylating agent therapy and allogeneic BMT,
which are the only disease-modifying therapies in MDS
[37,55,56]. We have recently investigated the impact of
TP53 VAF on outcomes in myeloid neoplasms [38]. In our
training set, TP53-mutant patients with a VAF > 40% had a
survival of 124 days versus an OS that was not reached in
patients with a VAF < 20% (hazard ratio [HR] = 3.52;
p = .01) and these findings were validated in a clinically
independent cohort (HR = 4.94; p = .01). Furthermore,
TP53 was predictive of survival as a continuous variable
and could further stratify patients independent of their IPSS
risk category. In a multivariable model that incorporated
age, sex, IPSS category, and allogeneic BMT status, a TP53
VAF > 40% was the strongest factor predicting inferior out-
comes (HR = 1.61; p < .0001). Of interest, TP53-mutant
patients with a VAF < 20% did not have an inferior survival,
even in univariable analysis, suggesting that VAF may be
the critical factor in identifying the truly high-risk patients.
In analysis of the total cohort of TP53-mutant patients
(n = 77), we identified an optimal VAF cutoff point of 20%
with a median OS with TP53 VAF < 20% of 685 days versus
VAF ofP20% of 183 days (p = .0036). Importantly, our study
highlighted that TP53 VAF can have significant prognostic
impact at the time of mutation sampling independent of
treatment and clinical characteristics. Indeed, recent novel
investigations identified the VAF of TP53 to be the most dra-
matically expanded clone at the time of progression to AML
or higher risk MDS (Figure 1) [57]. The majority of these
patients had subclonal TP53 mutations at diagnosis, and
94 D.A. Sallman, E. Padronthus could have important therapeutic implications. How-
ever, clonal burden is a dynamic process, and thus a key
consideration will be to carry out a future prospective clin-
ical study involving serial analysis of TP53 VAF and other
genes and their impact on survival.
Conclusions
Deciphering the molecular architecture of myeloid neo-
plasms has greatly enhanced our understanding of these dis-
eases and is now increasingly being used in the clinical
management of patients. Investigating the impact of VAF
for specific mutations has significantly advanced our under-
standing on how these mutations drive phenotype as well as
refine prognostication. International collaborative efforts
are underway to more definitively characterize the impact
of VAF in myeloid neoplasms with the goal of developing
novel therapies for patients.
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